Cooperative Agreement R43CA232935

New York University School of Medicine received a $703,227 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) awarded June 1, 2026, with a completion date of May 31, 2031. The grant supports development of an ultra-rapid droplet digital polymerase chain reaction (ddPCR) technology platform designed to deliver molecular-genetic profiling of cancer-driving mutations directly within the operating room during surgical resection...

This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...

Grant Award Summary The National Cancer Institute awarded the University of Connecticut Health Center a $414,585 Project Grant on May 6, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate a programmable enzyme-assisted mutation sequencing (PEAM-SEQ) diagnostic platform for noninvasive lung cancer detection. The grant supports development of PEAM-SEQ Version 2.0, an improved assay combining isothermal amplification, enzymatic cleavage, and...

FIND-SEQ Cell Sorting Technology Development and Commercialization The National Institute on Aging awarded Vivid Bioinnovations, PBC (operating as Fluid Discovery, Inc.) a $613,742 Project Grant under the Aging Research program (CFDA 93.866) on September 12, 2025, with a completion date of February 28, 2027. This Fast-Track Small Business Innovation Research (SBIR) award supports the translation and commercial development of FIND-SEQ, a novel cell sorting technology that enables isolation of...

The National Science Foundation (NSF) Engineering program (CFDA 47.041) awarded a $449,996.00 Project Grant to the Regents of the University of Minnesota, Office of Sponsored Projects Administration, to develop a highly sensitive, low-cost sensor platform to detect circulating tumor DNA (ctDNA), a biomarker for early cancer diagnosis. This project, in collaboration with researchers at the University of Cambridge, aims to combine microwave photonics (MWP) with polymer-based micro-ring resonator...

Federal Grant Award Summary The National Cancer Institute (NCI) awarded Massachusetts General Hospital a $2.86 million Project Grant under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on September 19, 2025, with completion targeted for August 31, 2029. The award funds development and validation of CAMPEX (CRISPR-Accelerated Molecular Profiling of Extracellular Vesicles), an innovative diagnostic platform designed to advance cancer detection and monitoring through liquid...

Federal Grant Award Summary Cereus Diagnostics Corp. received a $764,448 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on August 1, 2025, with completion targeted for July 31, 2028. The company is developing LUNG-FAST (Fragment Analysis, SNP, and Translocations), a rapid polymerase chain reaction (PCR)-based diagnostic test designed to detect clinically actionable lung cancer mutations including EGFR, KRAS, ALK,...

The National Cancer Institute (NCI) has awarded a $154,400 Project Grant (CFDA 93.396 Cancer Biology Research) to The Broad Institute, Inc. to support research on activating the SLFN12 RNase enzyme's cytotoxic effects against cancer cells. The research aims to determine whether SLFN12 dimerization can induce tRNA-Leu-TAA degradation and cancer cell death, independent of the PDE3A protein. Experiments will test if high SLFN12 expression alone can trigger this cytotoxic response, and whether a...

Federal Cooperative Agreement Summary The National Cancer Institute awarded Children's Hospital of Philadelphia $427,064 on July 16, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to conduct pilot and feasibility studies for a planned randomized controlled trial. This cooperative agreement supports the EDISYN (Early Detection in Syndromic Cancers) Consortium's work to evaluate the addition of circulating tumor DNA (ctDNA) screening to standard cancer screening...

Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $270,683 on May 5, 2026, under the Cancer Biology Research program (CFDA 93.396) to the New York Genome Center, Inc. (NYGC) for the development and validation of Paired-Break-Seq, a novel single-cell multiomics sequencing technique. This project, scheduled for completion on April 30, 2029, addresses a critical technical gap in cancer research by enabling simultaneous joint analysis of DNA double-strand breaks (DSBs),...